0001144204-15-060674.txt : 20151026 0001144204-15-060674.hdr.sgml : 20151026 20151026073015 ACCESSION NUMBER: 0001144204-15-060674 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20151026 DATE AS OF CHANGE: 20151026 EFFECTIVENESS DATE: 20151026 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc. CENTRAL INDEX KEY: 0001006281 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 650643773 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-33357 FILM NUMBER: 151174134 BUSINESS ADDRESS: STREET 1: 2 SNUNIT ST STREET 2: SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 20100 BUSINESS PHONE: 972-4-988-9488 MAIL ADDRESS: STREET 1: 2 SNUNIT ST STREET 2: SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 20100 FORMER COMPANY: FORMER CONFORMED NAME: ORTHODONTIX INC DATE OF NAME CHANGE: 19980422 FORMER COMPANY: FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP DATE OF NAME CHANGE: 19960124 DEFA14A 1 v422620_defa14a.htm DEFA14A

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

 

Filed by the Registrant  x

Filed by a Party other than the Registrant  ¨

Check the appropriate box:

 

¨ Preliminary Proxy Statement

 

¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

¨ Definitive Proxy Statement

 

ý Definitive Additional Materials

 

¨ Soliciting Material Pursuant to §240.14a-12

 

Protalix BioTherapeutics, Inc.

 


(Name of Registrant as Specified In Its Charter)

 


(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

x No fee required.

 

¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

  1) Title of each class of securities to which transaction applies:
  2) Aggregate number of securities to which transaction applies:
  3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set
    forth the amount on which the filing fee is calculated and state how it was determined):
  4) Proposed maximum aggregate value of transaction:
  5) Total fee paid:

 

¨ Fee paid previously with preliminary materials.

 

¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously.  Identify the previous filing by registration statement number, or the form or schedule and the date of its filing:

 

  1) Amount Previously Paid:
  2) Form, Schedule or Registration Statement No:
  3) Filing Party:
  4) Date Filed:

 

 

 

 

pro_58_color

 

 

 

 

 

October 21, 2015

 

 

Dear Protalix Shareholder,

 

According to our latest records, we have not yet received your proxy for the important Annual Meeting of shareholders of Protalix BioTherapeutics, Inc. to be held on November 8, 2015. Your Board of Directors has unanimously recommended that shareholders return the enclosed proxy card voting FOR all of the items on the agenda.

 

Your vote is important, no matter how many or how few shares you may own. Even if you have already done so, please vote TODAY by telephone, via the Internet, or by signing, dating and returning the enclosed proxy card in the envelope provided to ensure that your votes are validly received prior to the Annual Meeting.

 

Thank you for your support.

 

Sincerely,

 

 

Yossi Maimon

Vice President and Chief Financial Officer

 

 

 

 

REMEMBER:

You can vote your shares by telephone, or via the Internet.

Please follow the easy instructions on the enclosed card.

 

If you have any questions, or need assistance in voting

your shares, please call our proxy solicitor,

 

INNISFREE M&A INCORPORATED

TOLL-FREE, at 1-888-750-5834

 

 

 

 

GRAPHIC 2 image_003.jpg GRAPHIC begin 644 image_003.jpg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end GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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end